Development of a Risk Classifier to Predict Tumor Recurrence and Lenvatinib Benefits in Hepatocellular Carcinoma After Liver Transplantation.

Autor:	Deng, Yinan1 (AUTHOR), Yang, Jianming1 (AUTHOR), Chen, Yewu1 (AUTHOR), Wang, Jiangfeng1 (AUTHOR), Fu, Binsheng1 (AUTHOR), Zhang, Tong1 (AUTHOR), Yi, Shuhong1 (AUTHOR) yishuhong@163.com, Yang, Yang1,2 (AUTHOR) yysysu@163.com
Zdroj:	Transplantation Proceedings. Jan2023, Vol. 55 Issue 1, p153-163. 11p.
Databáze:	Academic Search Ultimate
Externí odkaz:	Zobrazit plný text záznamu Full Text from ScienceDirect